ZA201702762B - Reducing viscosity of pharmaceutical formulations - Google Patents
Reducing viscosity of pharmaceutical formulationsInfo
- Publication number
- ZA201702762B ZA201702762B ZA2017/02762A ZA201702762A ZA201702762B ZA 201702762 B ZA201702762 B ZA 201702762B ZA 2017/02762 A ZA2017/02762 A ZA 2017/02762A ZA 201702762 A ZA201702762 A ZA 201702762A ZA 201702762 B ZA201702762 B ZA 201702762B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical formulations
- reducing viscosity
- viscosity
- reducing
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067637P | 2014-10-23 | 2014-10-23 | |
| PCT/US2015/056972 WO2016065181A1 (en) | 2014-10-23 | 2015-10-22 | Reducing viscosity of pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201702762B true ZA201702762B (en) | 2022-12-21 |
Family
ID=54427875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/02762A ZA201702762B (en) | 2014-10-23 | 2017-04-19 | Reducing viscosity of pharmaceutical formulations |
Country Status (17)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015335743B2 (en) | 2014-10-23 | 2020-12-24 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| US11459401B2 (en) | 2016-10-06 | 2022-10-04 | Amgen Inc. | Reduced viscosity protein pharmaceutical formulations |
| JP7377596B2 (ja) * | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| WO2018200533A1 (en) | 2017-04-28 | 2018-11-01 | Amgen Inc. | Excipients to reduce the viscosity of antibody formulations and formulation compositions |
| MA48464A (fr) | 2017-04-28 | 2020-03-04 | Amgen Inc | Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques |
| EP3624846B1 (en) | 2017-05-16 | 2024-08-07 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan |
| WO2018229252A1 (en) | 2017-06-16 | 2018-12-20 | Zealand Pharma A/S | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
| JP6577683B2 (ja) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| WO2019106206A1 (en) | 2017-12-01 | 2019-06-06 | Fyb 202 Project Gmbh | Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody |
| PE20210462A1 (es) | 2018-07-05 | 2021-03-08 | Bayer Ag | METODO PARA LA PRODUCCION DE GRANULOS LIOFILIZADOS QUE COMPRENDEN UN ANTICUERPO ANTI-FACTOR XIa (FXIa) DE LA COAGULACION |
| KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
| EP3628683A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| CN113660927A (zh) * | 2019-04-23 | 2021-11-16 | 安进公司 | 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度 |
| AU2021219839A1 (en) * | 2020-02-13 | 2022-08-25 | Amgen Inc. | Formulations of human anti-TSLP antibodies and methods of treating inflammatory disease |
| KR102746418B1 (ko) * | 2020-12-03 | 2024-12-26 | 동국대학교 산학협력단 | N-아세틸-l-아르기닌을 포함하는 단백질 응집 억제용 조성물 |
| PE20240120A1 (es) * | 2021-03-09 | 2024-01-22 | Gi Innovation Inc | Formulacion de proteina de fusion que incluye el dominio extracelular de la subunidad alfa del receptor ige fc |
| CN117355321A (zh) * | 2021-04-09 | 2024-01-05 | 安万托特性材料股份有限公司 | 增强性能的赋形剂以及降低生物制剂的粘度和提高生物制剂的稳定性的方法 |
| WO2025175164A1 (en) * | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5078997A (en) | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
| EP1028748B1 (en) | 1997-11-07 | 2003-05-02 | Chiron Corporation | Compositions providing for increased igf-i solubility |
| US6767892B1 (en) * | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6159485A (en) * | 1999-01-08 | 2000-12-12 | Yugenic Limited Partnership | N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use |
| CA2403962C (en) | 2000-03-31 | 2009-12-15 | Kirin Beer Kabushiki Kaisha | Powdery preparation for transmucosal administration comprising a medicine of high molecular weight and exhibiting an improved storage stability |
| WO2002038170A2 (en) | 2000-11-07 | 2002-05-16 | Chiron Corporation | Stabilized inteferon compositions |
| DK1425389T3 (da) | 2001-08-23 | 2012-01-30 | Genmab As | Interleukin-15-(IL-15)-specifikke humane antistoffer |
| PT1946776T (pt) | 2002-02-27 | 2017-03-17 | Immunex Corp | Composição de tnfr-fc estabilizada compreendendo arginina |
| US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
| AU2004207003A1 (en) | 2003-01-30 | 2004-08-12 | Medimmune, Llc | Anti-integrin alphanubeta3 antibody formulations and uses thereof |
| BRPI0403964B8 (pt) * | 2003-04-04 | 2021-05-25 | Genentech Inc | formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige |
| US8084032B2 (en) | 2004-01-21 | 2011-12-27 | Ajinomoto Co., Inc. | Purification method which prevents denaturation of an antibody |
| US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| WO2006081171A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| JP5231810B2 (ja) * | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| CN101426527A (zh) * | 2006-02-03 | 2009-05-06 | 米迪缪尼有限公司 | 蛋白质制剂 |
| GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| EP2066684B1 (en) | 2006-05-11 | 2012-07-18 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| JP5059119B2 (ja) | 2006-12-14 | 2012-10-24 | シェーリング コーポレイション | 操作された抗ｔｓｌｐ抗体 |
| EP2170957A1 (en) | 2007-06-20 | 2010-04-07 | Irm, Llc | Methods and compositions for treating allergic diseases |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| CN101969971A (zh) | 2007-11-30 | 2011-02-09 | 雅培制药有限公司 | 蛋白制剂及其制备方法 |
| RU2537139C2 (ru) * | 2008-01-15 | 2014-12-27 | Эбботт Гмбх Унд Ко.Кг | Порошковые белковые композиции и способы их получения |
| TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Ｐｃｓｋ９拮抗劑類 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| JP2011067202A (ja) | 2009-08-31 | 2011-04-07 | Sanyo Chem Ind Ltd | タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法 |
| EP2501367B1 (en) * | 2009-11-17 | 2015-01-21 | Ipsen Pharma S.A.S. | Formulation for HGH and RHIGF-1 combination |
| JP6078344B2 (ja) * | 2010-02-04 | 2017-02-08 | ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト | 免疫グロブリン製剤 |
| EP3216462A3 (en) * | 2010-02-26 | 2017-12-20 | Novo Nordisk A/S | Stable antibody containing compositions |
| US20130171128A1 (en) * | 2010-03-02 | 2013-07-04 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| WO2011139718A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
| AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
| CN108771655A (zh) * | 2011-10-28 | 2018-11-09 | 诚信生物公司 | 含有氨基酸的蛋白质制剂 |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| US20150150982A1 (en) | 2012-06-12 | 2015-06-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
| US20150004174A1 (en) | 2013-06-28 | 2015-01-01 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| AU2015335743B2 (en) | 2014-10-23 | 2020-12-24 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| EP3226895B1 (en) | 2014-12-03 | 2020-07-22 | CSL Behring AG | Pharmaceutical product with increased stability comprising immunoglobulins |
| MA46359A (fr) | 2016-09-29 | 2019-08-07 | Amgen Inc | Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation |
| US11459401B2 (en) | 2016-10-06 | 2022-10-04 | Amgen Inc. | Reduced viscosity protein pharmaceutical formulations |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
-
2015
- 2015-10-22 AU AU2015335743A patent/AU2015335743B2/en active Active
- 2015-10-22 EP EP21175309.0A patent/EP3909611B1/en active Active
- 2015-10-22 JP JP2017522169A patent/JP2017531682A/ja active Pending
- 2015-10-22 CA CA2964786A patent/CA2964786C/en active Active
- 2015-10-22 EA EA201790787A patent/EA033444B1/ru not_active IP Right Cessation
- 2015-10-22 ES ES21175309T patent/ES2964713T3/es active Active
- 2015-10-22 CN CN202210048275.7A patent/CN114569716A/zh active Pending
- 2015-10-22 KR KR1020177011706A patent/KR102534017B1/ko active Active
- 2015-10-22 EA EA202191513A patent/EA202191513A1/ru unknown
- 2015-10-22 CN CN201580057461.5A patent/CN107206070B/zh active Active
- 2015-10-22 SG SG11201703152RA patent/SG11201703152RA/en unknown
- 2015-10-22 EP EP15790759.3A patent/EP3209332B1/en active Active
- 2015-10-22 MX MX2017005243A patent/MX388858B/es unknown
- 2015-10-22 EA EA201991447A patent/EA038462B1/ru unknown
- 2015-10-22 MA MA054716A patent/MA54716A/fr unknown
- 2015-10-22 IL IL287947A patent/IL287947B2/en unknown
- 2015-10-22 WO PCT/US2015/056972 patent/WO2016065181A1/en not_active Ceased
- 2015-10-22 BR BR112017008125-3A patent/BR112017008125B1/pt active IP Right Grant
- 2015-10-22 US US15/521,057 patent/US11813328B2/en active Active
-
2017
- 2017-04-13 IL IL251726A patent/IL251726B/en unknown
- 2017-04-19 ZA ZA2017/02762A patent/ZA201702762B/en unknown
- 2017-04-20 CL CL2017000984A patent/CL2017000984A1/es unknown
- 2017-04-21 MX MX2021015789A patent/MX2021015789A/es unknown
-
2019
- 2019-08-02 CL CL2019002190A patent/CL2019002190A1/es unknown
- 2019-10-21 JP JP2019191701A patent/JP6965321B2/ja active Active
-
2021
- 2021-02-15 AU AU2021200990A patent/AU2021200990B2/en active Active
- 2021-10-19 JP JP2021170676A patent/JP7411615B2/ja active Active
-
2023
- 2023-10-24 US US18/383,121 patent/US12318447B2/en active Active
-
2025
- 2025-05-30 US US19/223,578 patent/US20250345421A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287947A (en) | Viscosity reduction of pharmaceutical preparations | |
| IL246978A0 (en) | New paracetamol formulations | |
| ZA201605300B (en) | Pharmaceutical compositions comprising azd9291 | |
| GB201618482D0 (en) | Pharmaceutical compositions | |
| GB201419257D0 (en) | Pharmaceutical compositions | |
| GB201409471D0 (en) | Pharmaceutical composition | |
| IL249553A0 (en) | Pharmaceutical preparations | |
| GB201409488D0 (en) | Pharmaceutical composition | |
| GB201409485D0 (en) | Pharmaceutical composition | |
| ZA201606075B (en) | Pharmaceutical compositions of sitagliptin | |
| IL256115A (en) | Pharmaceutical formulations of injectable lapmoline | |
| HUE039791T2 (hu) | Levocetirizint tartalmazó gyógyszerészeti készítmények | |
| IL250817A0 (en) | pharmaceutical preparations | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| GB201718468D0 (en) | Stable liquid pharmaceutical compositions of bortezomb | |
| PL3200772T3 (pl) | Kompozycje farmaceutyczne zawierające alpelisyb | |
| GB201506755D0 (en) | Novel pharmaceutical formulation | |
| LT3089740T (lt) | Farmacinė kompozicija | |
| GB2529605B (en) | Pharmaceutical composition | |
| GB201417589D0 (en) | Pharmaceutical Formulations | |
| HK1242572A1 (en) | Reducing viscosity of pharmaceutical formulations | |
| GB201407741D0 (en) | Novel drug formulation | |
| GB201400951D0 (en) | Novel drug formulation | |
| SG2014014872A (en) | Pharmaceutical compositions | |
| GB201408432D0 (en) | Pharmaceutical compositions |